Overview of US Patent 10,376,661
US Patent 10,376,661, filed by Merck Sharp & Dohme Corp. and granted on August 6, 2019, covers a novel class of compounds, their methods of synthesis, and therapeutic uses, primarily targeting metabolic and inflammatory diseases. This patent emphasizes its claims over specific chemical structures, broad methodologies, and potential medical applications.
Scope and Claims Breakdown
1. Core Invention
The patent protects a class of substituted heterocyclic compounds. These compounds are characterized by specific structural features involving a heteroaryl group attached to a core scaffold, which exhibits activity against particular enzymes or biological targets, such as kinases or receptor modulations relevant to diseases like diabetes and inflammation.
2. Claim Types
-
Compound Claims: Cover individual chemical entities with defined substituents, often numbered and substituted at specific positions. The claims specify chemical formulae and allowable substitutions, providing a broad protection net.
-
Method Claims: Encompass synthesis methods for these compounds, including reaction steps and conditions.
-
Use Claims: Protect therapeutic applications, such as methods of treating diseases involving certain biological pathways.
-
Manufacturing Claims: Cover processes to prepare the compounds, including intermediates.
3. Claim Scope Analysis
| Category |
Breadth & Limitations |
Key Details |
| Compound Claims |
Broad but specific to defined chemical structures |
Claims include derivatives of a heteroaryl scaffold with various functional group substitutions. |
| Method Claims |
Narrower, focusing on synthesis protocols |
Cover steps involving particular reagents, catalysts, or reaction conditions. |
| Use Claims |
Medium breadth, targeting specific indications |
Claims extend to treating conditions like type 2 diabetes or inflammatory diseases with these compounds. |
| Manufacturing Processes |
Specific to particular synthetic routes |
Processes involve known reactions but with particular conditions to produce claimed compounds. |
4. Patent Term and Priority
- Priority date: September 20, 2016
- Patent term expiry: September 20, 2036 (20-year term from filing, adjusted for patent term adjustments)
5. Limitations and Considerations
- The claims do not cover all possible heterocyclic modifications but focus on certain core structures.
- Synthesis pathways are limited to the methods described and similar variations are possibly unprotected.
- Therapeutic scope is explicitly linked to conditions involving specific biological pathways targeted by the compounds.
Patent Landscape and Comparative Analysis
1. Similar Patents and Related Families
- Related patent families filed by Merck or competitors have emerged, focusing on kinase inhibitors and anti-inflammatory agents.
- Examples include WO2019172094 (anti-inflammatory compounds) and US2019034824 (kinase inhibitor derivatives).
2. Patent Strength and Risks
- The broad compound claims provide robust market protection but depend on patentable novelty and non-obviousness over prior art.
- The patent does not preclude use of similar scaffolds not falling within the exact claim structure, maintaining competitive freedom.
3. Litigation & Patent Challenges
- No widely reported litigations directly challenging US 10,376,661.
- Potential for opposition based on prior art in chemical synthesis or similar therapeutic compounds.
4. Patent Expiration & Competitive Outlook
- With a 2036 expiry, market exclusivity persists into the mid-2030s.
- Patent cliffs are unlikely before this date, but competitors may patent alternative structures or synthesis methods to circumvent claims.
Key Patent Claim Highlights
- Claims focus on specific heteroaryl derivatives with particular substituents.
- Therapeutic claims extend to methods of treating diseases associated with kinase activity or receptor modulation.
- Composition claims include pharmaceutical formulations with the compounds.
Implications for R&D and Commercialization
- The broad compound claims position Merck strongly in metabolic and inflammatory indications.
- Synthesis and use claims enable a variety of patent strategies to defend or extend coverage.
- Competing firms must explore alternative scaffolds, synthesis routes, or targets to design around this patent.
Summary Table
| Aspect |
Details |
| Patent Number |
10,376,661 |
| Filing Date |
September 20, 2016 |
| Issue Date |
August 6, 2019 |
| Priority Date |
September 20, 2016 |
| Expiry Date |
September 20, 2036 |
| Key Focus |
Heterocyclic compounds, methods of synthesis, therapeutic use |
| Main Claim Scope |
Specific chemical structures, methods, and indications |
| Related Patents |
WO2019172094, US2019034824 |
| Marketed Drugs or Candidates |
No approved drugs directly under this patent; relates to drug candidates under development |
Key Takeaways
- The patent covers a broad class of heterocyclic compounds plausible for treating inflammation and metabolic disorders.
- Claims encompass chemical structures, synthesis methods, and therapeutic applications, providing extensive protection.
- Competitors must develop alternative structures or processes to avoid infringement.
- The patent's expiration in 2036 allows for a significant period of market exclusivity.
- The landscape includes closely related patents targeting similar disease pathways, indicating active R&D competition.
FAQs
Q1: Can the claims of US 10,376,661 be challenged based on prior art?
Yes, claims are subject to challenge if prior patents or publications disclose similar compounds, synthesis methods, or therapeutic uses, especially considering the broad chemical definitions.
Q2: Does the patent cover biological or biosimilar versions?
The patent primarily covers small molecules with specific chemical structures. Biospecific or biological therapeutics are not directly protected unless they relate to the same targets and pathways.
Q3: Are synthesis method claims enforceable?
Yes, but their scope can be limited if alternative, non-infringing synthesis routes exist that do not use the patented methods.
Q4: How does this patent affect generic drug development?
Generic manufacturers must design novel compounds or synthesis pathways that do not infringe claims, potentially delaying entry until patent expiry or licensing agreements.
Q5: What strategic options exist for competitors?
Develop structurally distinct compounds outside the scope of the claims, modify synthesis methods, or target different biological pathways related to the same indications.
References
[1] US Patent 10,376,661.
[2] Related patent families and applications.
[3] Industry reports on kinase inhibitors and inflammatory agents.
